Abacus Life (ABL) Expected to Announce Earnings on Thursday

Abacus Life (NASDAQ:ABL) will likely be releasing its Q3 2025 results after the market closes on Thursday, November 6th. Analysts expect Abacus Life to post earnings of $0.18 per share and revenue of $47.42 million for the quarter. Interested persons may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 6, 2025 at 5:00 PM ET.

Abacus Life (NASDAQ:ABL) last issued its earnings results on Thursday, August 7th. The company reported $0.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.16 by $0.06. Abacus Life had a positive return on equity of 17.65% and a negative net margin of 0.72%.The business had revenue of $56.23 million during the quarter, compared to analysts’ expectations of $43.38 million. On average, analysts expect Abacus Life to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Abacus Life Stock Up 0.2%

Shares of NASDAQ:ABL opened at $5.33 on Thursday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.76 and a current ratio of 0.76. Abacus Life has a 1 year low of $4.60 and a 1 year high of $9.61. The stock has a market capitalization of $515.73 million, a P/E ratio of -88.83 and a beta of -0.01. The stock has a 50-day simple moving average of $6.19 and a 200-day simple moving average of $6.49.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ABL. Piper Sandler decreased their target price on Abacus Life from $10.00 to $9.00 and set an “overweight” rating for the company in a report on Thursday, October 9th. Wall Street Zen raised Abacus Life from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Abacus Life in a research report on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Abacus Life has a consensus rating of “Moderate Buy” and a consensus price target of $12.67.

Hedge Funds Weigh In On Abacus Life

A number of institutional investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. raised its position in shares of Abacus Life by 13.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,928,293 shares of the company’s stock valued at $14,443,000 after purchasing an additional 221,712 shares in the last quarter. Mendon Capital Advisors Corp raised its position in shares of Abacus Life by 13.9% in the 2nd quarter. Mendon Capital Advisors Corp now owns 1,619,342 shares of the company’s stock valued at $8,323,000 after purchasing an additional 197,171 shares in the last quarter. Curi Capital LLC raised its position in shares of Abacus Life by 3.9% during the 2nd quarter. Curi Capital LLC now owns 1,325,000 shares of the company’s stock valued at $6,810,000 after acquiring an additional 50,000 shares in the last quarter. Bank of America Corp DE raised its position in shares of Abacus Life by 155.2% during the 2nd quarter. Bank of America Corp DE now owns 667,895 shares of the company’s stock valued at $3,433,000 after acquiring an additional 406,143 shares in the last quarter. Finally, Marshall Wace LLP raised its position in shares of Abacus Life by 175.5% during the 2nd quarter. Marshall Wace LLP now owns 657,251 shares of the company’s stock valued at $3,378,000 after acquiring an additional 418,660 shares in the last quarter.

About Abacus Life

Abacus Life, Inc operates as an alternative asset manager specializing in life insurance products. It purchases life insurance policies from consumers seeking liquidity and manages policies over time via trading, holding, and/or servicing. The company was founded in 2004 and is based in Orlando, Florida.